Novartis renews WHO medicine donation pledge with aim of ending leprosy

  •  Novartis leprosy medicine donation program with WHO extended to 2025
  • Program has already treated over 7 million patients since 2000
  • New evidence from contact tracing and preventive treatment program shows route to accelerate elimination

Basel, January 29, 2021 — A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 …

/by

Novartis 2020 Financial Results

Media Releases

Download the media release
English (PDF 0.2 MB )  |  Deutsch (PDF 0.2 MB)  |  Français (PDF 0.2 MB)

Condensed financial …

/by

Novartis 2020 Financial Results

Media Releases

Download the media release
English (PDF 0.2 MB )  |  Deutsch (PDF 0.2 MB)  |  Français (PDF 0.2 MB)

Condensed financial …

/by

Novartis ranks second in 2021 Access to Medicine Index

Dr. Juliet Akoth examines a patient during a home visit in Kitui, Kenya

Novartis ranked second in the 2021 Access to Medicine Index (ATMIndex), maintaining the same leading position as in 2018, in recognition of its long-standing efforts to improve …

/by

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

  • Full year net sales from continuing operations¹ up 3% (cc², +3% USD):
    • Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)
    • Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)
    • Sandoz …
/by

Digital innovation looks set to dominate the 2021 healthcare agenda

COVID-19 was a catalyst for change in healthcare during 2020 – an accelerator for digital health.

2021 looks set to continue the revolution – exploiting ‘an explosion of interest, traction and scale’ in the potential for digital innovation to meet global healthcare needs.

In early 2020, as the virus spread exponentially, the world was forced to work virtually, where possible. Digital solutions were needed fast – not just to support remote-working, but to keep the very fabric of business, healthcare, education, and essential services in operation.

For Novartis and many …

/by

Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa

  • Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients 
  • Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

  • Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by March 1, 2021

Basel, January 19, 2021 — Novartis and GSK today announced the …

/by

Novartis Gene Therapies Recommits to Global Managed Access Program for 2021

Dear SMA community,

One year ago we launched a global Managed Access Program (MAP), the first for a one-time gene therapy, to make Zolgensma® (onasemnogene abeparvovec) available to eligible patients with spinal muscular atrophy (SMA) who are under the age of two in countries where Zolgensma has not received regulatory approval. Today we are pleased to share that we allocated 100 doses free-of-charge in 2020, and …

/by

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)

  • Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1
     
  • Currently there are limited approved therapies for patients with CSU, also known as chronic idiopathic urticaria (CIU)
     
  • Breakthrough Therapy designation suggests ligelizumab has the potential to provide a substantial benefit over existing available treatments
     
  • U.S. regulatory filing in CSU is anticipated in 2022 …
/by

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

  • Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth

  • Novartis secures development and commercialization rights in North America, Europe, and Japan

  • Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations

  • Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial …
/by